2022
Single agent PD-1 blockade as curative-intent treatment in mismatch repair deficient locally advanced rectal cancer.
Cercek A, Lumish M, Sinopoli J, Weiss J, Shia J, Stadler Z, Yaeger R, Smith J, Saltz L, El Dika I, Crane C, Romesser P, Iyer K, Paty P, Garcia-Aguilar J, Gonen M, Gollub M, Weiser M, Schalper K, Diaz L. Single agent PD-1 blockade as curative-intent treatment in mismatch repair deficient locally advanced rectal cancer. Journal Of Clinical Oncology 2022, 40: lba5-lba5. DOI: 10.1200/jco.2022.40.17_suppl.lba5.Peer-Reviewed Original ResearchPD-1 blockadeAdvanced rectal cancerSingle-agent PD-1 blockadeClinical complete responseRectal cancerCo-primary endpointsComplete responseAnti-PD-1 monoclonal antibodyProspective phase II studyPD-1 monoclonal antibodyMismatch repair-deficient colorectal cancersCurative-intent treatmentPhase II studySerious adverse eventsCase of progressionEvidence of tumorDigital rectal examDeficient colorectal cancerMetastatic settingNeoadjuvant chemotherapyAdverse eventsCheckpoint blockadeII studySurgical resectionRectal adenocarcinomaPD-1 Blockade in Mismatch Repair–Deficient, Locally Advanced Rectal Cancer
Cercek A, Lumish M, Sinopoli J, Weiss J, Shia J, Lamendola-Essel M, El Dika IH, Segal N, Shcherba M, Sugarman R, Stadler Z, Yaeger R, Smith JJ, Rousseau B, Argiles G, Patel M, Desai A, Saltz LB, Widmar M, Iyer K, Zhang J, Gianino N, Crane C, Romesser PB, Pappou EP, Paty P, Garcia-Aguilar J, Gonen M, Gollub M, Weiser MR, Schalper KA, Diaz LA. PD-1 Blockade in Mismatch Repair–Deficient, Locally Advanced Rectal Cancer. New England Journal Of Medicine 2022, 386: 2363-2376. PMID: 35660797, PMCID: PMC9492301, DOI: 10.1056/nejmoa2201445.Peer-Reviewed Original ResearchMeSH KeywordsAntibodies, Monoclonal, HumanizedAntineoplastic AgentsAntineoplastic Combined Chemotherapy ProtocolsChemoradiotherapyDNA Mismatch RepairHumansNeoadjuvant TherapyNeoplasm StagingNeoplasms, Second PrimaryProgrammed Cell Death 1 ReceptorProspective StudiesRectal NeoplasmsRectumTreatment OutcomeConceptsAdvanced rectal cancerClinical complete responsePD-1 blockadeRectal cancerComplete responseSingle-agent PD-1 blockadeAnti-PD-1 monoclonal antibodyProspective phase 2 studyMismatch repair-deficient colorectal cancersDeath-1 blockadePrimary end pointCase of progressionEvidence of tumorPathological complete responsePhase 2 studyDigital rectal examinationDuration of responseMismatch repair deficientMagnetic resonance imagingNeoadjuvant chemotherapyUndergone surgeryAdverse eventsCheckpoint blockadeMetastatic diseaseSurgical resection
2011
Monoclonal Gammopathy of Undetermined Significance Does Not Affect Outcomes in Patients Undergoing Solid Organ Transplants
Jimenez-Zepeda VH, Heilman RL, Engel RA, Carey EJ, Freeman C, Rakela J, Mulligan DC, Fonseca R, Stewart AK. Monoclonal Gammopathy of Undetermined Significance Does Not Affect Outcomes in Patients Undergoing Solid Organ Transplants. Transplantation 2011, 92: 570-574. PMID: 21712755, DOI: 10.1097/tp.0b013e318225db2c.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAgedBlood Protein ElectrophoresisChildDisease ProgressionFemaleHumansImmunosuppression TherapyLymphoproliferative DisordersMaleMiddle AgedMonoclonal Gammopathy of Undetermined SignificanceMultiple MyelomaRisk FactorsTransplantation ImmunologyTransplantsTreatment OutcomeYoung AdultConceptsSolid organ transplant patientsPosttransplant lymphoproliferative disorderOrgan transplant patientsTransplant patientsLymphoproliferative disordersMultiple myelomaUndetermined significanceMonoclonal gammopathyPlasma cell proliferative disorderLiver transplant candidatesOutcomes of patientsCase of progressionSolid organ transplantsPlasma cell dyscrasiaCell proliferative disorderMGUS patientsTransplant candidatesClinical courseLate malignancyLifelong riskImmune suppressionRelative riskCell dyscrasiaMonoclonal clonesOrgan transplants
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply